

Todd A Fehniger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6561229/publications.pdf>

Version: 2024-02-01

167
papers

16,814
citations

38742

50
h-index

15732

125
g-index

173
all docs

173
docs citations

173
times ranked

20086
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 1/dose expansion trial of brentuximab vedotin andÂlenalidomide in relapsed or refractory diffuse large B-cell lymphoma. <i>Blood</i> , 2022, 139, 1999-2010.	1.4	17
2	Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. <i>Blood</i> , 2022, 139, 1177-1183.	1.4	41
3	Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia. <i>Science Translational Medicine</i> , 2022, 14, eabm1375.	12.4	49
4	Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant. <i>Blood</i> , 2022, 139, 1670-1683.	1.4	57
5	A novel fusion protein scaffold 18/12/TxM activates the IL-12, IL-15, and IL-18 receptors to induce human memory-like natural killer cells. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 585-596.	4.4	5
6	Metabolic Biomarkers Assessed with PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients with Diffuse Large B-Cell Lymphoma. <i>Cancers</i> , 2022, 14, 2932.	3.7	5
7	A Systemic Protein Deviation Score Linked to PD-1+ CD8+ T Cell Expansion That Predicts Overall Survival in Diffuse Large B Cell Lymphoma. <i>Med</i> , 2021, 2, 180-195.e5.	4.4	0
8	Flow cytometry-based ex vivo murine NK cell cytotoxicity assay. <i>STAR Protocols</i> , 2021, 2, 100262.	1.2	8
9	Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 3339-3350.	7.0	26
10	Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Bloodâ€Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies. <i>Clinical Cancer Research</i> , 2021, 27, 3744-3756.	7.0	69
11	Memory-like Differentiation Enhances NK Cell Responses to Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 4859-4869.	7.0	33
12	Reliance on Cox10 and oxidative metabolism for antigen-specific NK cell expansion. <i>Cell Reports</i> , 2021, 35, 109209.	6.4	16
13	Abstract SY30-02: NK cells remember: Engineering NK cell memory-like responses for cancer immunotherapy. , 2021, , .		0
14	A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2021, 9, 1071-1087.	3.4	36
15	End of Treatment Peripheral Blood TCR Evaluation for Minimal Residual Disease Evaluation in Peripheral T-Cell Lymphomas. <i>Blood</i> , 2021, 138, 3506-3506.	1.4	2
16	Predictors of Relapse and Survival Following Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 1832-1832.	1.4	0
17	Eomes and T-Bet Expression Are Required By Mature Primary Human NK Cells for Anti-Leukemia Responses In Vivo. <i>Blood</i> , 2021, 138, 194-194.	1.4	0
18	Cytokine-Induced Memory-like NK Cells Have a Distinct Single Cell Transcriptional Profile and Persist for Months in Adult and Pediatric Leukemia Patients after Adoptive Transfer. <i>Blood</i> , 2021, 138, 3825-3825.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Memory-like natural killer cells for cancer immunotherapy. <i>Seminars in Hematology</i> , 2020, 57, 185-193.	3.4	48
20	A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2223-2228.	2.0	3
21	Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia. <i>Cancer Discovery</i> , 2020, 10, 1854-1871.	9.4	83
22	65. Accurate neoantigen prediction depends on mutation position relative to patient-specific MHC anchor locations. <i>Cancer Genetics</i> , 2020, 244, 24-25.	0.4	0
23	Stage-Specific Requirement for Eomes in Mature NK Cell Homeostasis and Cytotoxicity. <i>Cell Reports</i> , 2020, 31, 107720.	6.4	40
24	Interleukin-15 superagonist (N-803) treatment of PML and JCV in a post-allogeneic hematopoietic stem cell transplant patient. <i>Blood Advances</i> , 2020, 4, 2387-2391.	5.2	11
25	Potently Cytotoxic Natural Killer Cells Initially Emerge from Erythro-Myeloid Progenitors during Mammalian Development. <i>Developmental Cell</i> , 2020, 53, 229-239.e7.	7.0	63
26	CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. <i>Blood</i> , 2020, 136, 2308-2318.	1.4	133
27	Blood natural killer cell deficiency reveals an immunotherapy strategy for atopic dermatitis. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	57
28	<i>KIR B</i> donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation. <i>Blood Advances</i> , 2020, 4, 740-754.	5.2	42
29	End of Treatment Peripheral Blood T-Cell Receptor Gene Rearrangement Evaluation for Minimal Residual Disease Evaluation in Peripheral T-Cell Lymphomas. <i>Blood</i> , 2020, 136, 30-31.	1.4	2
30	CD56 regulates human NK cell cytotoxicity through Pyk2. <i>ELife</i> , 2020, 9, .	6.0	30
31	531...AFM13-targeted blood and cord-blood-derived memory-like NK cells as therapy for CD30+ malignancies. , 2020, , .		0
32	A Pilot Study of Acalabrutinib with Bendamustine/Rituximab Followed By Cytarabine/Rituximab (R-ABC) for Untreated Mantle Cell Lymphoma. <i>Blood</i> , 2020, 136, 8-9.	1.4	1
33	MicroRNA-142 Is Critical for the Homeostasis and Function of Type 1 Innate Lymphoid Cells. <i>Immunity</i> , 2019, 51, 479-490.e6.	14.3	39
34	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). <i>European Journal of Immunology</i> , 2019, 49, 1457-1973.	2.9	766
35	Mystery Solved: IL-15. <i>Journal of Immunology</i> , 2019, 202, 3125-3126.	0.8	6
36	Open-Sourced CIVIC Annotation Pipeline to Identify and Annotate Clinically Relevant Variants Using Single-Molecule Molecular Inversion Probes. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-12.	2.1	6

#	ARTICLE	IF	CITATIONS
37	ONTOGENY IS A CRITICAL DETERMINANT OF NATURAL KILLER CELL POTENTIAL AND FUNCTION. <i>Experimental Hematology</i> , 2019, 76, S87.	0.4	0
38	Cytokine-Induced Memory-like (ML) NK Cells Persist for > 2 Months Following Adoptive Transfer into Leukemia Patients with a MHC-Compatible Hematopoietic Cell Transplant (HCT). <i>Blood</i> , 2019, 134, 1954-1954.	1.4	19
39	Adoptively Transferred Donor-Derived Cytokine Induced Memory-like NK Cells Persist and Induce Remission in Pediatric Patient with Relapsed Acute Myeloid Leukemia after Hematopoietic Cell Transplantation. <i>Blood</i> , 2019, 134, 3307-3307.	1.4	9
40	Chimeric Antigen Receptor Modified Memory-like (CAR-ML) NK Cells Exhibit Potent Responses to NK-Resistant Tumors. <i>Blood</i> , 2019, 134, 869-869.	1.4	1
41	Primary Human NK Cell Gene-Editing Reveals a Critical Role for NKG2A in Cytokine-Induced Memory-like NK Cell Responses. <i>Blood</i> , 2019, 134, 3237-3237.	1.4	6
42	System-Level Disease-Driven Immune Signatures in Patients with Diffuse Large B-Cell Lymphoma Associated with Poor Survival. <i>Blood</i> , 2019, 134, 2897-2897.	1.4	0
43	Potently Cytotoxic Natural Killer Cell Potential Initially Emerges from Erythro-Myeloid Progenitors during Mammalian Development. <i>Blood</i> , 2019, 134, 2464-2464.	1.4	0
44	Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas. <i>Blood</i> , 2019, 134, 1550-1550.	1.4	1
45	First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. <i>Blood</i> , 2018, 131, 2515-2527.	1.4	307
46	Is There Natural Killer Cell Memory and Can It Be Harnessed by Vaccination?. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a029512.	5.5	8
47	A Phase 1 Trial of CNDO-109â€“Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1581-1589.	2.0	50
48	Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow. <i>Haematologica</i> , 2018, 103, e270-e273.	3.5	1
49	Minimal activity of nanoparticle albumin-bound (nab) paclitaxel in relapsed or refractory lymphomas: results of a phase-I study. <i>Leukemia and Lymphoma</i> , 2018, 59, 357-362.	1.3	7
50	Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. <i>Blood</i> , 2018, 131, 182-190.	1.4	130
51	A deep learning approach to automate refinement of somatic variant calling from cancer sequencing data. <i>Nature Genetics</i> , 2018, 50, 1735-1743.	21.4	62
52	Ontogeny as a Critical Determinant of Natural Killer Cell Potential and Function. <i>Experimental Hematology</i> , 2018, 64, S106.	0.4	0
53	Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). <i>Blood Advances</i> , 2018, 2, 1705-1718.	5.2	16
54	Comment on: Evidence of innate lymphoid cell redundancy in humans. <i>Nature Immunology</i> , 2018, 19, 788-789.	14.5	8

#	ARTICLE	IF	CITATIONS
55	<i>MIR142</i> Loss-of-Function Mutations Derepress <i>ASH1L</i> to Increase <i>HOXA</i> Gene Expression and Promote Leukemogenesis. <i>Cancer Research</i> , 2018, 78, 3510-3521.	0.9	39
56	Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas Including AITL and DLBCL: Phase I Results. <i>Blood</i> , 2018, 132, 2929-2929.	1.4	0
57	Ontogeny As a Critical Determinant of Natural Killer Cell Potential and Function. <i>Blood</i> , 2018, 132, 1271-1271.	1.4	0
58	Transcriptional and post-transcriptional regulation of NK cell development and function. <i>Clinical Immunology</i> , 2017, 177, 60-69.	3.2	23
59	T Cell-Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 648-653.	2.0	38
60	Cytokine-Induced Memory-Like Differentiation Enhances Unlicensed Natural Killer Cell Antileukemia and <i>Fcγ3R11a</i> -Triggered Responses. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 398-404.	2.0	48
61	Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. <i>Blood</i> , 2017, 129, 473-483.	1.4	147
62	Guidelines for the use of flow cytometry and cell sorting in immunological studies [*] . <i>European Journal of Immunology</i> , 2017, 47, 1584-1797.	2.9	505
63	Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen. <i>Cancer Medicine</i> , 2017, 6, 2814-2821.	2.8	21
64	CD70 turns on NK cells to attack lymphoma. <i>Blood</i> , 2017, 130, 238-239.	1.4	4
65	Mir-223 regulates the number and function of myeloid-derived suppressor cells in multiple sclerosis and experimental autoimmune encephalomyelitis. <i>Acta Neuropathologica</i> , 2017, 133, 61-77.	7.7	72
66	A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 347-353.	0.4	23
67	Glycolytic requirement for NK cell cytotoxicity and cytomegalovirus control. <i>JCI Insight</i> , 2017, 2, .	5.0	90
68	CD56 ^{bright} NK cells exhibit potent antitumor responses following IL-15 priming. <i>Journal of Clinical Investigation</i> , 2017, 127, 4042-4058.	8.2	236
69	Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. <i>Haematologica</i> , 2016, 101, e465-e468.	3.5	54
70	Comparison of Outcomes after Peripheral Blood Haploidentical versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia: A Retrospective Single-Center Review. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1696-1701.	2.0	50
71	Human Adaptive Natural Killer Cells: Beyond NKG2C. <i>Trends in Immunology</i> , 2016, 37, 351-353.	6.8	27
72	<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>New England Journal of Medicine</i> , 2016, 375, 2023-2036.	27.0	663

#	ARTICLE	IF	CITATIONS
73	Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. <i>Science Translational Medicine</i> , 2016, 8, 357ra123.	12.4	621
74	Harnessing NK Cell Memory for Cancer Immunotherapy. <i>Trends in Immunology</i> , 2016, 37, 877-888.	6.8	90
75	Severe Cytokine-Release Syndrome after T Cellâ€“Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Antiâ€“IL-6 Therapy Is Safe and Well Tolerated. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1851-1860.	2.0	135
76	The IL-15-Based ALT-803 Complex Enhances FcÎ³RIIIa-Triggered NK Cell Responses and <i>In Vivo</i> Clearance of B Cell Lymphomas. <i>Clinical Cancer Research</i> , 2016, 22, 596-608.	7.0	130
77	Exome Sequencing of Hodgkin's and Non-Hodgkin Composite Lymphomas Identifies Shared Somatic Mutations Indicative of Common Founding Precursors. <i>Blood</i> , 2016, 128, 5285-5285.	1.4	0
78	Risk Factors for the Development of and Outcomes of Patients Who Develop Severe Cytokine Release Syndrome after Peripheral Blood Haploidentical Donor Transplant. <i>Blood</i> , 2016, 128, 3419-3419.	1.4	0
79	Human CD56bright NK Cells Acquire Potent Anti-Leukemia Functionality Following IL-15 Priming. <i>Blood</i> , 2016, 128, 550-550.	1.4	0
80	The Use of CD34+-Selected Stem Cell Boosts Following HLA-Haploidentical Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 4697-4697.	1.4	0
81	Improving natural killer cell cancer immunotherapy. <i>Current Opinion in Organ Transplantation</i> , 2015, 20, 671-680.	1.6	44
82	PTEN regulates natural killer cell trafficking in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E700-E709.	7.1	34
83	Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma. <i>Journal of Geriatric Oncology</i> , 2015, 6, 211-218.	1.0	47
84	Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1425-1430.	2.0	12
85	Human Cytokine-Induced Memory-Like Natural Killer Cells. <i>Journal of Innate Immunity</i> , 2015, 7, 563-571.	3.8	81
86	MicroRNA-15/16 Antagonizes <i>Myb</i> To Control NK Cell Maturation. <i>Journal of Immunology</i> , 2015, 195, 2806-2817.	0.8	44
87	Memory NK Cells Take Out the (Mitochondrial) Garbage. <i>Immunity</i> , 2015, 43, 218-220.	14.3	3
88	Human Cytokine-Induced Memory-like NK Cells Exhibit <i>In Vivo</i> Anti-Leukemia Activity in Xenografted NSG Mice and in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 101-101.	1.4	4
89	Use of Post-Transplant Cyclophosphamide (PTCy) with Mycophenolate Mofetil and Tacrolimus in HLA Matched Allogeneic Hematopoietic Cell Transplant Is Safe and Associated with Acceptable Transplant Outcomes. <i>Blood</i> , 2015, 126, 1950-1950.	1.4	5
90	'First-in-human' phase I dose escalation trial of IL-15N72D/IL-15RÎ±-Fc superagonist complex (ALT-803) demonstrates immune activation with anti-tumor activity in patients with relapsed hematological malignancy. <i>Blood</i> , 2015, 126, 1957-1957.	1.4	7

#	ARTICLE	IF	CITATIONS
91	A Phase I Trial of Brentuximab Vedotin in Combination with Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 3988-3988.	1.4	5
92	Recurrent Somatic Genomic Alterations in Follicular NHL (FL) Revealed By Exome and Custom-Capture Next Generation Sequencing. <i>Blood</i> , 2015, 126, 574-574.	1.4	2
93	Dynamic Changes in Clonal Clearance with Decitabine Therapy in AML and MDS Patients. <i>Blood</i> , 2015, 126, 689-689.	1.4	1
94	Addition of Mycophenolate Mofetil to Methotrexate and Tacrolimus Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2015, 126, 3144-3144.	1.4	0
95	T-Cell Replete Peripheral Blood Haploidentical Donor Transplant Is Frequently Associated with Cytokine Release Syndrome Which Responds to Anti-IL-6 Therapy. <i>Blood</i> , 2015, 126, 3106-3106.	1.4	0
96	Utilizing Cytokines to Function-Enable Human NK Cells for the Immunotherapy of Cancer. <i>Scientifica</i> , 2014, 2014, 1-18.	1.7	104
97	Protective Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients Is Influenced by Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 46-52.	2.0	86
98	microRNA management of NK cell developmental and functional programs. <i>European Journal of Immunology</i> , 2014, 44, 2862-2868.	2.9	37
99	Preactivation with IL-12, IL-15, and IL-18 Induces CD25 and a Functional High-Affinity IL-2 Receptor on Human Cytokine-Induced Memory-like Natural Killer Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 463-473.	2.0	215
100	Human Cytokine-Induced Memory-like (CIML) NK Cells Are Active Against Myeloid Leukemia in Vitro and in Vivo. <i>Blood</i> , 2014, 124, 1117-1117.	1.4	9
101	Preliminary Results of a Phase 1/2 Clinical Trial of Cnd-109-Activated Allogeneic Natural Killer Cells in High Risk Acute Myelogenous Leukemia Patients in First Complete Remission. <i>Blood</i> , 2014, 124, 2320-2320.	1.4	5
102	A Phase I/II Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL). <i>Blood</i> , 2014, 124, 3099-3099.	1.4	3
103	The IL-15 Superagonist ALT-803 Enhances NK Cell ADCC and in Vivo Clearance of B Cell Lymphomas Directed By an Anti-CD20 Monoclonal Antibody. <i>Blood</i> , 2014, 124, 807-807.	1.4	3
104	PTEN Regulates Natural Killer Cell Trafficking in Vivo. <i>Blood</i> , 2014, 124, 753-753.	1.4	0
105	MicroRNA-155 Tunes Both the Threshold and Extent of NK Cell Activation via Targeting of Multiple Signaling Pathways. <i>Journal of Immunology</i> , 2013, 191, 5904-5913.	0.8	51
106	Lenalidomide-mediated enhanced translation of C/EBP β -p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. <i>Blood</i> , 2013, 121, 159-169.	1.4	56
107	Abrogation of human NK cell development. <i>Blood</i> , 2013, 121, 2579-2580.	1.4	1
108	Extracellular microRNAs turn on NK cells via TLR1. <i>Blood</i> , 2013, 121, 4612-4613.	1.4	5

#	ARTICLE	IF	CITATIONS
109	Unraveling the molecular events leading to the genesis of large granular lymphocytic leukemia reveals a new treatment strategy. <i>Haematologica</i> , 2013, 98, 159-159.	3.5	1
110	MicroRNA regulation of natural killer cells. <i>Frontiers in Immunology</i> , 2013, 4, 44.	4.8	53
111	Mir-15/16 Antagonizes Myb To Control Natural Killer Cell Differentiation and Maturation. <i>Blood</i> , 2013, 122, 17-17.	1.4	4
112	IL-15 Primes a Highly Potent Anti-Leukemia Response By CD56bright NK Cells. <i>Blood</i> , 2013, 122, 2283-2283.	1.4	3
113	Human Cytokine-Induced Memory-Like (CIML) NK Cells Exhibit Potent Anti-Leukemia Cytotoxicity and Maintain Memory-Like Functionality After Adoptive Transfer Into Immunodeficient NOD-SCID-Gc ^{-/-} (NSC) Mice. <i>Blood</i> , 2013, 122, 4501-4501.	1.4	1
114	MicroRNA-Deficient NK Cells Exhibit Decreased Survival but Enhanced Function. <i>Journal of Immunology</i> , 2012, 188, 3019-3030.	0.8	62
115	Natural Killer Cell Regulation by MicroRNAs in Health and Disease. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-12.	3.0	30
116	Cytokine activation induces human memory-like NK cells. <i>Blood</i> , 2012, 120, 4751-4760.	1.4	492
117	T Cell-Depleted Partial Matched Unrelated Donor Transplant for Advanced Myeloid Malignancy: KIR Ligand Mismatch and Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 937-943.	2.0	25
118	A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2012, 120, 1623-1623.	1.4	7
119	A Phase I Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL). <i>Blood</i> , 2012, 120, 1644-1644.	1.4	5
120	Cytokine Activation and CD16 Cross-Linking Leads to the Generation of Human Memory-Like NK Cells. <i>Blood</i> , 2012, 120, 3291-3291.	1.4	1
121	Cytokine Activation Induces CD25 Expression and a Signaling-Competent High-Affinity IL-2 Receptor On CD56dim Human NK Cells. <i>Blood</i> , 2012, 120, 2159-2159.	1.4	1
122	Prognostic Significance of FDG-PET in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Standard Salvage Chemotherapy and Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1646-1652.	2.0	92
123	A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. <i>Blood</i> , 2011, 117, 1828-1833.	1.4	104
124	Human NK cells: SET to kill. <i>Blood</i> , 2011, 117, 2297-2298.	1.4	13
125	A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. <i>Blood</i> , 2011, 118, 5119-5125.	1.4	181
126	MicroRNA-Deficient Murine NK Cells Exhibit Impaired Development and Survival but Enhanced IFN- γ Production In Vitro and In Vivo. <i>Blood</i> , 2011, 118, 357-357.	1.4	2

#	ARTICLE	IF	CITATIONS
127	Latent herpesvirus infection arms NK cells. <i>Blood</i> , 2010, 115, 4377-4383.	1.4	62
128	Complete characterization of the microRNAome in a patient with acute myeloid leukemia. <i>Blood</i> , 2010, 116, 5316-5326.	1.4	63
129	Granzyme B is not required for regulatory T cell-mediated suppression of graft-versus-host disease. <i>Blood</i> , 2010, 115, 1669-1677.	1.4	29
130	Next-generation sequencing identifies the natural killer cell microRNA transcriptome. <i>Genome Research</i> , 2010, 20, 1590-1604.	5.5	144
131	The NK Cell MicroRNA Transcriptome Defined by Next-Generation Sequencing Identifies IL-15-Signaled Alterations In Mature MiR-223 Expression, and MiR-223 as a Potential Regulator of Murine Granzyme B. <i>Blood</i> , 2010, 116, 104-104.	1.4	0
132	Differential Expression of Granzyme B and C in Murine Cytotoxic Lymphocytes. <i>Journal of Immunology</i> , 2009, 182, 6287-6297.	0.8	37
133	Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. <i>Blood</i> , 2009, 113, 1002-1005.	1.4	79
134	Prognostic Significance of PET Imaging in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Salvage Chemotherapy and Autologous Stem Cell Transplantation.. <i>Blood</i> , 2009, 114, 3417-3417.	1.4	1
135	A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma.. <i>Blood</i> , 2009, 114, 3693-3693.	1.4	12
136	A Phase II Study of High Dose Lenalidomide as Initial Therapy for Acute Myeloid Leukemia in Patients > 60 Years Old.. <i>Blood</i> , 2009, 114, 842-842.	1.4	4
137	Comprehensive Evaluation of MicroRNA Genes and Gene Expression Using Next Generation Sequencing in a Patient with Acute Myelogenous Leukemia.. <i>Blood</i> , 2009, 114, 271-271.	1.4	2
138	Latent Murine Herpesvirus-4 Infection Arms NK Cells.. <i>Blood</i> , 2009, 114, 3678-3678.	1.4	0
139	A Phase II Multicenter Study of Lenalidomide in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL): Preliminary Results. <i>Blood</i> , 2008, 112, 2595-2595.	1.4	8
140	Acquisition of Murine NK Cell Cytotoxicity Requires the Translation of a Pre-existing Pool of Granzyme B and Perforin mRNAs. <i>Immunity</i> , 2007, 26, 798-811.	14.3	391
141	Granzyme B and Perforin Are Important for Regulatory T Cell-Mediated Suppression of Tumor Clearance. <i>Immunity</i> , 2007, 27, 635-646.	14.3	715
142	Chronic lymphocytosis of functionally immature natural killer cells. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 120, 924-931.	2.9	5
143	Phase II Study of High Dose Lenalidomide as Initial Treatment for Older Acute Myeloid Leukemia Patients: Early Results Show a Significant Reduction of Bone Marrow Blasts after 14 Days of Therapy.. <i>Blood</i> , 2007, 110, 916-916.	1.4	8
144	In Vivo Murine Cytokine Models and the Genesis of Cancer. , 2007, , 199-209.		0

#	ARTICLE	IF	CITATIONS
145	Hop Cleavage and Function in Granzyme B-induced Apoptosis. <i>Journal of Biological Chemistry</i> , 2006, 281, 37130-37141.	3.4	19
146	Murine NK Cells Require Activation-Dependent Expression of Granzyme B and Perforin To Become Potent Cytotoxic Effectors. <i>Blood</i> , 2006, 108, 920-920.	1.4	0
147	NK cell and DC interactions. <i>Trends in Immunology</i> , 2004, 25, 47-52.	6.8	395
148	Biology and clinical impact of human natural killer cells. <i>International Journal of Hematology</i> , 2003, 78, 7-17.	1.6	93
149	CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. <i>Blood</i> , 2003, 101, 3052-3057.	1.4	750
150	New directions in natural killer cell-based immunotherapy of human cancer. <i>Expert Opinion on Biological Therapy</i> , 2003, 3, 237-250.	3.1	32
151	In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. <i>Blood</i> , 2002, 100, 3633-3638.	1.4	382
152	Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. <i>Blood</i> , 2002, 100, 1935-1947.	1.4	449
153	Interleukin-2 and interleukin-15: immunotherapy for cancer. <i>Cytokine and Growth Factor Reviews</i> , 2002, 13, 169-183.	7.2	251
154	Natural killer cells: biology and application in stem-cell transplantation. <i>Cytotherapy</i> , 2002, 4, 445-446.	0.7	17
155	Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. <i>Clinical Cancer Research</i> , 2002, 8, 2812-9.	7.0	40
156	Fatal Leukemia in Interleukin-15 Transgenic Mice. <i>Blood Cells, Molecules, and Diseases</i> , 2001, 27, 223-230.	1.4	43
157	Ontogeny and Expansion of Human Natural Killer Cells: Clinical Implications. <i>International Reviews of Immunology</i> , 2001, 20, 503-536.	3.3	33
158	Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset. <i>Blood</i> , 2001, 97, 3146-3151.	1.4	1,201
159	Interleukin 15: biology and relevance to human disease. <i>Blood</i> , 2001, 97, 14-32.	1.4	851
160	The biology of human natural killer-cell subsets. <i>Trends in Immunology</i> , 2001, 22, 633-640.	6.8	2,520
161	Fatal Leukemia in Interleukin 15 Transgenic Mice Follows Early Expansions in Natural Killer and Memory Phenotype Cd8+ T Cells. <i>Journal of Experimental Medicine</i> , 2001, 193, 219-232.	8.5	335
162	Cutting Edge: IL-15 Costimulates the Generalized Shwartzman Reaction and Innate Immune IFN- β Production In Vivo. <i>Journal of Immunology</i> , 2000, 164, 1643-1647.	0.8	59

#	ARTICLE	IF	CITATIONS
163	Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. <i>Journal of Clinical Investigation</i> , 2000, 106, 117-124.	8.2	85
164	Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. <i>Cancer Immunology, Immunotherapy</i> , 1998, 46, 318-326.	4.2	79
165	Flt3 Ligand Promotes the Generation of a Distinct CD34+Human Natural Killer Cell Progenitor That Responds to Interleukin-15. <i>Blood</i> , 1998, 92, 3647-3657.	1.4	198
166	Stem Cell Factor Enhances Interleukin-2-Mediated Expansion of Murine Natural Killer Cells In Vivo. <i>Blood</i> , 1997, 90, 3647-3653.	1.4	32
167	CD56bright natural killer cell subsets: Characterization of distinct functional responses to interleukin-2 and the c-kit ligand. <i>European Journal of Immunology</i> , 1997, 27, 354-360.	2.9	108